CADE probes drugmaker for price hike
Brazil’s public prosecutor has complained against Gilead Sciences to the country’s competition enforcer, reportedly about the drugmaker raising the price of a hepatitis C medication by more than 1400%.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.